Putting Tuberculosis (TB) to Rest: Transformation of the Sleep Aid, Ambien, and "anagrams" Generated Potent Antituberculosis Agents

ACS Infectious Diseases

Volumn 1, Issue 2, 2016, Pages 85-90

  Moraski, Garrett C ^a,e   Miller, Patricia A ^a   Bailey, Mai Ann ^b   Ollinger, Juliane ^b   Parish, Tanya ^b   Boshoff, Helena I ^c   Cho, Sanghyun ^d   Anderson, Jeffery R ^d   Mulugeta, Surafel ^d   Franzblau, Scott G ^d   Miller, Marvin J ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e MONTANA STATE UNIVERSITY   (United States)

Author keywords

Ambien; anti TB; imidazopyridine analogues; tuberculosis; zolpidem

Indexed keywords

IMIDAZO[1,2 A]PYRIDINE 3 CARBOXYAMIDE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ZOLPIDEM TARTRATE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; ISOMER; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

EID: 84969257176     PISSN: None     EISSN: 23738227     Source Type: Journal    
DOI: 10.1021/id500008t     Document Type: Article

References (38)

1. Wilsey, A. M. (2012) Half in love with easeful death: tuberculosis in literature. Humanities Capstone Projects, Paper 11; http://commons.pacificu.edu/cashu/11.
2. Martinez, G. G. (2013) Romanticizing tuberculosis: poetry, prose, opera, and society of the romantic era; https://digital.library.txstate.edu/handle/10877/4661.
3. Latimer, D. (1990) Erotic susceptibility and tuberculosis: literary images of a pathology MLN 105, 1016-1031 http://www.jstor.org/stable/2905165
4. Byrne, K. (2011) Tuberculosis and the Victorian Literary Imagination; Cambridge University Press: Cambridge, UK.
5. Brontë, C. (2005) Jane Eyre; Barnes & Noble Classics: New York.
6. Toth, A., Fackelmann, J., Pigott, W., and Tolomeo, O. (2004) Tuberculosis prevention and treatment Can. Nurse 100, 27-30
7. World Health Organization (WHO). ((2012) Global tuberculosis report; http://www.who.int/tb/publications/global-report/gtbr12-main.pdf.
8. Stop TB Partnership. ((2012) Combating tuberculosis in children, Stop TB Partnership, Geneva, Switzerland; http://www.who.int/tb/challenges/childtb-factsheet.pdf.
9. Moraski, G. C., Markley, L. D., Hipskind, P. A., Boshoff, H., Cho, S., Franzblau, S. G., and Miller, M. J. (2011) Advent of imidazo[1,2-a]pyridine-3-carboxamides with potent multi- and extended drug resistant antituberculosis activity ACS Med. Chem. Lett. 2, 466-470 10.1021/ml200036r
10. Moraski, G. C., Markley, L. D., Chang, M., Cho, S., Franzblau, S. G., Hwang, C. H., Boshoff, H., and Miller, M. J. (2012) Generation and exploration of new classes of antitubercular agents: the optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds Bioorg. Med. Chem. 7, 2214-2220 10.1016/j.bmc.2012.02.025
11. Ollinger, J., Bailey, M.-A., Moraski, G. C., Casey, A., Florio, S., Alling, T., Miller, M. J., and Parish, T. (2013) A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis PLoS One 8 e60531 10.1371/journal.pone.0060531
12. Moraski, G. C., Markley, L. D., Cramer, J., Hipskind, P. A., Boshoff, H., Bailey, M.-A., Alling, T., Ollinger, J., Parish, T., and Miller, M. J. (2013) Advancement of imidazo[1,2-a]pyridines with improved pharmacokinetics and nanomolar activity against Mycobacterium tuberculosis ACS Med. Chem. Lett. 4, 675-679 10.1021/ml400088y
13. Sanger, D. J., Benavides, J., Perrault, G., Morel, E., Cohen, C., Joly, D., and Zivkovic, B. (1994) Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: evidence for the functional significance of receptor subtypes Neurosci. Biobehav. Rev. 18, 355-372 10.1016/0149-7634(94)90049-3
14. Byrnes, J. J., Greenblatt, D. J., and Miller, L. G. (1992) Benzodiazepine receptor binding of non-benzodiazepines in vivo: alpidem, zolpidem, and zopiclone Brain Res. Bull. 29, 905-908
15. Hoehns, J. D. and Perry, P. J. (1993) Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia Clin. Pharm. 12, 814-828
16. Von Moltke, L. L., Greenblatt, D. J., Granda, B. W., Duan, S. X., Grassi, J. M., Venkatakrishnan, K., Harmatz, J. S., and Shader, R. I. (1999) Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations Br. J. Clin. Pharmacol. 48, 89-97 10.1046/j.1365-2125.1999.00953.x
17. Wagner, J. and Wagner, M. L. (2000) Non-benzodiazepines for the treatment of insomnia Sleep Med. Rev. 4, 551-581 10.1053/smrv.2000.0126
18. Mak, P. M., Rao, S. P. S., Tan, M.-P., Lin, X., Chyba, J., Tay, J., Ng, S.-H., Tan, B.-H., Cherian, J., Duraiswamy, J., Bifani, P., Vim, V., Lee, B.-H., Ma, N.-L., Beer, D., Thayalan, P., Kuhen, K., Chatterjee, A., Supek, F., Glynne, R., Zheng, J., Boshoff, H. I., Barr, C. E., Dick, T., Pethe, K., and Camacho, L. R. (2012) A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis ACS Chem. Bio. 7, 1190-1197 10.1021/cb2004884
19. Abrahams, K. A., Cox, J. A. G., Spivey, V. L., Loman, N. J., Patten, M. J., Constantinidoou, C., Fernandex, R., Alemparte, C., Remuinan, M. J., Barros, D., Ballell, L., and Besra, G. S. (2012) Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB PLoS One 7 e52951 10.1371/journal.pone.0052951
20. Cope, D. W., Wulff, P., Oberto, A., Aller, M. I., Capogna, M., Ferraguti, F., Halbsgurth, C., Hoeger, H., Jolin, H. E., Jones, A., Mckenzie, A. N. J., Ogris, W., Poeltl, A., Sinkkonen, S. T., Vekovischeva, O. Y., Korpi, E. R., Sieghart, W., Sigel, E., Somogyi, P., and Wisden, W. (2004) Abolition of zolpidem sensitivity in mice with a point mutation in the GABAA receptor gamma2 subunit Neuropharmacology 47, 17-34 10.1016/j.neuropharm.2004.03.007
21. Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., Jiricek, J., Jung, J., Jeon, H. K., Cechetto, J., Lee, H., Kempf, M., Jackson, M., Lanaerts, A. J., Pham, H., Jones, V., Seo, M. J., Kim, Y. M., Seo, M., Seo, J. J., Park, D., Ko, Y., Choi, I., Kim, R., Kim, S. Y., Lim, S.-B., Yim, S.-A., Nam, J., Kang, H., Kwon, H., Oh, C.-T., Cho, Y., Jang, Y., Kim, J., Chua, A., Tan, B. H., Nanjundappa, M. B., Rao, S. P. S., Barnes, W. S., Wintjens, R., Walker, J. R., Alonso, S., Lee, S., Kim, J., Oh, S., Oh, T., Nehrbass, U., Han, S.-J., No, Z., Lee, J., Brodin, P., Cho, S.-N., Nam, K., and Kim, J. (2013) Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis Nat. Med. 19, 1157-1160 10.1038/nm.3262
22. Cheng, Y., Moraski, G. C., Cramer, J., Miller, M. J., and Schorey, J. S. (2014) Bactericidal activity of an imidazo[1,2-a]pyridine using a mouse M. tuberculosis infection model PLoS One 9 e87483 10.1371/journal.pone.0087483
23. The screening data were found in the collaborative drug discovery (CDD) portal as a public molecule SMR0000469145 (or CDD-730); https://app.collaborativedrug.com/. For more information on CDD, see: Ekins, S., Kaneko, T., Lipinski, C. A., Bradford, J., Dole, K., Spektor, A., Gregory, K., Blondeau, D., Ernst, S., Yang, J., Goncharoff, N., Hohmana, M. M., and Bunin, B. A. (2010) Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis Mol. BioSyst. 6, 2316-2324, DOI: 10.1039/c0mb00104j.
24. De Voss, J. J., Rutter, K., Schroeder, B. G., Su, H., Zhu, Y., and Barry, C. E. (2000) The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages Proc. Natl. Acad. Sci. U.S.A. 97, 1252-1257 10.1073/pnas.97.3.1252
25. Franzblau, S. G., DeGroote, M. A., Cho, S. H., Andries, K., Nuermberger, E., Orme, I. M., Mdluli, K., Angulo-Barturen, I., Dick, T., Dartois, V., and Lenaerts, A. J. (2012) Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis Tuberculosis 92, 453-488 10.1016/j.tube.2012.07.003
26. Pethe, K., Sequeira, P. C., Agarwalla, S., Rhee, K., Kuhen, K., Phong, W. Y., Patel, V., Beer, D., Walker, J. R., Duraiswamy, J., Jiricek, J., Keller, T. H., Chatterjee, A., Tan, M. P., Ujjini, M., Roa, S. P. S., Camacho, L., Bifani, P., Mak, A. P., Ma, I., and Barnes, S. W. (2010) A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy Nat. Commun. 57, 1-8 10.1038/ncomms1060
27. Solovev, V. N. and Zueva, V. S. (1965) Significance of the degree of aeration of media for the antibacterial action of antitubercular agents Biull. Eksp. Biol. Med. 63-65
28. Aoyagi, A. (1977) Clinical significance of antitubercular agents and protein binding Kekkaku 52, 101-103
29. Abignente, E., de Caprariis, P., De Martino, G., and Patscot, R. (1987) Research on heterocyclic compounds. XXI. Synthesis of imidazo[2,1-b]benzothiazole and imidazo[2,1-b]thiazole derivatives J. Heterocycl. Chem. 24, 155-158
30. Rey, M., Rossler, A., Derungs, G., and Pak, J. K. (2002) Process for the preparation of imidazopyridines. WO 2002014306 A1 (Cilag Ag).
31. Alok, S., Sakhardande, R., Santosh, C., Chaudhari, H., and Jadhav, M. (2007) Process for the preparation of imidazopyridines. WO 2007023504 A1 (Saxena Alok).
32. Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., Kreiswirth, B. N., Barry, C. E., and Baker, W. R. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 405, 962-966 10.1038/35016103
33. Ogawa, T. and Otani, N. (1961) Studies on inactivation of antitubercular agents in media. III. Examination of the media with effects of inactivating antitubercular agents Kekkaku 138-141
34. Cohn, D. L., Catlin, B. J., Peterson, K. L., Judson, F. N., and Sbarbaro, J. A. (1990) A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen Ann. Int. Med. 112, 407-415 10.7326/0003-4819-76-3-112-6-407
35. Lechartier, B., Hartkoorn, R. C., and Cole, S. T. (2012) In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 56, 5790-5793 10.1128/AAC.01476-12
36. Lilienkampf, A., Mao, J., Wan, B., Wang, Y., Franzblau, S. G., and Kozikowski, A. P. (2009) Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis J. Med. Chem. 52, 2109-2118 10.1021/jm900003c
37. Espinel-Ingroff, A. (2006) Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B J. Clin. Microbiol. 44, 3616-3622 10.1128/JCM.01187-06
38. Arora, K., Ochoa-Montano, B., Tsang, P. S., Blundell, T. L., Dawes, S. S., Mizrahi, V., Bayliss, T., Mackenzie, C. J., Cleghorn, L. A. T., Ray, P. C., Wyatt, P. G., Uh, E., Lee, J., Barry, C. E., and Boshoff, H. I. (2014) Respiratory flexibility in response to inhibition of cytochrome c oxidase in Mycobacterium tuberculosis Antimicrob. Agents Chemother. 58, 6962-6965 10.1128/AAC.03486-14